Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL DS versus SULTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL DS versus SULTRIN.
GANTANOL-DS vs SULTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid, thereby blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, converting dihydrofolate to tetrahydrofolate. This sequential blockade produces bactericidal activity.
Sultrin (sulfanilamide, sulfathiazole, sulfacetamide) is a triple sulfonamide combination that acts as a bacteriostatic agent. It inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolic acid. This disrupts nucleic acid synthesis in susceptible bacteria.
2 g (DS strength: 2 g sulfamethoxazole/400 mg trimethoprim) orally every 12 hours for 14-21 days for Pneumocystis jirovecii pneumonia.
Intravaginal administration: one applicatorful (approximately 5 g) of Sultrin Triple Sulfa Cream (containing sulfathiazole, sulfacetamide, and sulfabenzamide) intravaginally once or twice daily for 4 to 7 days. Oral: Not applicable.
None Documented
None Documented
10-12 hours (sulfamethoxazole component); prolonged in renal impairment (up to 30 hours with CrCl <15 mL/min).
Terminal half-life 8-12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Primarily renal (70-100%) as unchanged drug and inactive metabolites (sulfamethoxazole N4-acetyl and glucuronide conjugates); <5% biliary/fecal.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic